LivaNova plc Secures Regulatory Approval for Essenz Perfusion System in China, Expanding Market Reach for Heart-Lung Machines

Reuters

2025/08/18

LivaNova plc Secures Regulatory Approval for Essenz Perfusion System in China, Expanding Market Reach for Heart-Lung Machines

LivaNova PLC, a leader in medical technology, has announced the commercial launch of its Essenz™ Perfusion System in China, following regulatory approval from China's National Medical Products Administration (NMPA). This launch marks a significant step for LivaNova as China represents the second-largest market for the company's heart-lung machines, following the United States. The Essenz Perfusion System, designed with input from over 300 perfusionists worldwide, offers a patient-tailored perfusion approach that enhances clinical workflows and patient care during cardiopulmonary bypass procedures. With this approval, the system is now available in several major markets, including Europe, Canada, Australia, Japan, and the United Arab Emirates, supporting over 100,000 patients globally since its launch in February 2023.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Livanova plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20250818865276) on August 18, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2560900035"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2560900035\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2560900035?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-18 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2560900035","market":"fut","top_or_hot":-1,"title":"LivaNova plc Secures Regulatory Approval for Essenz Perfusion System in China, Expanding Market Reach for Heart-Lung Machines","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      LivaNova plc Secures Regulatory Approval for Essenz Perfusion System in China, Expanding Market Reach for Heart-Lung Machines\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/LIVN\">LivaNova PLC</a>, a leader in medical technology, has announced the commercial launch of its Essenz™ Perfusion System in China, following regulatory approval from China's National Medical Products Administration (NMPA). This launch marks a significant step for LivaNova as China represents the second-largest market for the company's heart-lung machines, following the United States. The Essenz Perfusion System, designed with input from over 300 perfusionists worldwide, offers a patient-tailored perfusion approach that enhances clinical workflows and patient care during cardiopulmonary bypass procedures. With this approval, the system is now available in several major markets, including Europe, Canada, Australia, Japan, and the United Arab Emirates, supporting over 100,000 patients globally since its launch in February 2023.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Livanova plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20250818865276) on August 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LivaNova plc Secures Regulatory Approval for Essenz Perfusion System in China, Expanding Market Reach for Heart-Lung Machines</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLivaNova plc Secures Regulatory Approval for Essenz Perfusion System in China, Expanding Market Reach for Heart-Lung Machines\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-18 21:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      LivaNova plc Secures Regulatory Approval for Essenz Perfusion System in China, Expanding Market Reach for Heart-Lung Machines\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/LIVN\">LivaNova PLC</a>, a leader in medical technology, has announced the commercial launch of its Essenz™ Perfusion System in China, following regulatory approval from China's National Medical Products Administration (NMPA). This launch marks a significant step for LivaNova as China represents the second-largest market for the company's heart-lung machines, following the United States. The Essenz Perfusion System, designed with input from over 300 perfusionists worldwide, offers a patient-tailored perfusion approach that enhances clinical workflows and patient care during cardiopulmonary bypass procedures. With this approval, the system is now available in several major markets, including Europe, Canada, Australia, Japan, and the United Arab Emirates, supporting over 100,000 patients globally since its launch in February 2023.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Livanova plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20250818865276) on August 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LIVN","symbol_name":"LivaNova PLC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250818:nNDL1gF1mZ:1","article_id":"2560900035","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2560900035","pubTimestamp":1755522095,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"LivaNova plc Secures Regulatory Approval for Essenz Perfusion System in China, Expanding Market Reach for Heart-Lung Machines. LivaNova PLC, a leader in medical technology, has announced the commercial launch of its Essenz Perfusion System in China, following regulatory approval from China's National Medical Products Administration . This launch marks a significant step for LivaNova as China represents the second-largest market for the company's heart-lung machines, following the United States. The Essenz Perfusion System, designed with input from over 300 perfusionists worldwide, offers a patient-tailored perfusion approach that enhances clinical workflows and patient care during cardiopulmonary bypass procedures. With this approval, the system is now available in several major markets, including Europe, Canada, Australia, Japan, and the United Arab Emirates, supporting over 100,000 patients globally since its launch in February 2023.Disclaimer: This news brief was created by Public T","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LIVN":"LivaNova PLC","BK4082":"医疗保健设备"},"translate_title":"LivaNova plc的Essenz灌注系统在中国获得监管部门批准，扩大心肺机的市场范围","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LIVN":0.9},"content_text":"LivaNova plc Secures Regulatory Approval for Essenz Perfusion System in China, Expanding Market Reach for Heart-Lung Machines\n    \n\nLivaNova PLC, a leader in medical technology, has announced the commercial launch of its Essenz™ Perfusion System in China, following regulatory approval from China's National Medical Products Administration (NMPA). This launch marks a significant step for LivaNova as China represents the second-largest market for the company's heart-lung machines, following the United States. The Essenz Perfusion System, designed with input from over 300 perfusionists worldwide, offers a patient-tailored perfusion approach that enhances clinical workflows and patient care during cardiopulmonary bypass procedures. With this approval, the system is now available in several major markets, including Europe, Canada, Australia, Japan, and the United Arab Emirates, supporting over 100,000 patients globally since its launch in February 2023.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Livanova plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20250818865276) on August 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}